These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12495173)

  • 21. Torsade de pointes during sevoflurane anesthesia and fluconazole infusion in a patient with long QT syndrome. A case report.
    Tacken MC; Bracke FA; Van Zundert AA
    Acta Anaesthesiol Belg; 2011; 62(2):105-8. PubMed ID: 21919379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Torsades de pointes heart arrhythmia caused by terodiline].
    Braadland H
    Tidsskr Nor Laegeforen; 1992 Jan; 112(2):197-8. PubMed ID: 1566246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythromycin induced Torsades de Pointes: case report and review of the literature.
    Rezkalla MA; Pochop C
    S D J Med; 1994 May; 47(5):161-4. PubMed ID: 8047870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Torsades de pointes after adenosine administration.
    Teodorovich N; Margolin E; Kogan Y; Paz O; Swissa M
    J Electrocardiol; 2016; 49(2):171-3. PubMed ID: 26850499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
    Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
    J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
    Johansson M; Carlsson L
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged QT: A rare cause of cardiac arrest.
    Carlquist J
    JAAPA; 2015 Aug; 28(8):. PubMed ID: 26208008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.
    Yalta K; Turgut O; Yilmaz A; Yilmaz MB; Kendirlioglu O; Karadas F
    Int J Cardiol; 2007 Apr; 116(3):e95-7. PubMed ID: 17126428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long QT syndrome and torsade de pointes in a patient receiving fluconazole.
    Wassmann S; Nickenig G; Böhm M
    Ann Intern Med; 1999 Nov; 131(10):797. PubMed ID: 10577320
    [No Abstract]   [Full Text] [Related]  

  • 33. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haloperidol-induced torsade de pointes.
    O'Brien JM; Rockwood RP; Suh KI
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
    Amankwa K; Krishnan SC; Tisdale JE
    Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Torsades de pointes in congenital long QT syndrome following low-dose orphenadrine.
    Luzza F; Raffa S; Saporito F; Oreto G
    Int J Clin Pract; 2006 May; 60(5):606-8. PubMed ID: 16700864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.
    Kurita T; Ohe T; Shimizu W; Suyama K; Aihara N; Takaki H; Kamakura S; Shimomura K
    Pacing Clin Electrophysiol; 1997 Mar; 20(3 Pt 1):695-705. PubMed ID: 9080496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined use of astemizole and ketoconazole resulting in torsade de pointes.
    Tsai WC; Tsai LM; Chen JH
    J Formos Med Assoc; 1997 Feb; 96(2):144-6. PubMed ID: 9071844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The QT interval and torsade de pointes.
    Moss AJ
    Drug Saf; 1999; 21 Suppl 1():5-10; discussion 81-7. PubMed ID: 10597863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.